PDS Biotech Reports An Inducement Grant Under Nasdaq

FLORHAM PARK, N.J., Oct. 07, 2022 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy firm creating a rising pipeline of focused immunotherapies for most cancers and infectious illness, as we speak introduced that PDS Biotech granted nonstatutory inventory choices to Rory Cullinane, PDS Biotech’s Vice President, Quality Assurance, to buy 70,000 shares of PDS Biotech widespread inventory as a fabric inducement to his employment with PDS Biotech and in accordance with Nasdaq Listing Rule 5635(c)(4) and PDS Biotech’s 2019 Inducement Plan, as amended.

The inventory possibility has an train worth of $3.62, the closing worth of PDS Biotech’s widespread inventory on October 5, 2022 and vests over a four-year interval, with one-quarter of the shares vesting on the primary anniversary of the grant date (October 5, 2022) and the remaining shares vesting month-to-month over the 36-month interval thereafter, topic to continued employment with PDS Biotech by the relevant vesting dates.

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy firm creating a rising pipeline of focused most cancers and infectious illness immunotherapies primarily based on our proprietary Versamune® and Infectimune™ T cell-activating expertise platforms. We consider our focused Versamune® primarily based candidates have the potential to beat the constraints of present immunotherapy by inducing giant portions of high-quality, potent polyfunctional tumor particular CD4+ helper and CD8+ killer T cells. To date, our lead Versamune® scientific candidate, PDS0101, has demonstrated the potential to scale back tumors and stabilize illness together with permitted and investigational therapeutics in sufferers with a broad vary of HPV-positive cancers in a number of Phase 2 scientific trials. Our Infectimune™ primarily based vaccines have additionally demonstrated the potential to induce not solely strong and sturdy neutralizing antibody responses, but in addition highly effective T cell responses, together with long-lasting reminiscence T cell responses in pre-clinical research thus far. To be taught extra, please go to www.pdsbiotech.com or comply with us on Twitter at @PDSBiotech.

Forward Looking Statements

This communication comprises forward-looking statements (together with inside the which means of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) regarding PDS Biotechnology Corporation (the “Company”) and different issues. These statements might focus on targets, intentions and expectations as to future plans, tendencies, occasions, outcomes of operations or monetary situation, or in any other case, primarily based on present beliefs of the Company’s administration, in addition to assumptions made by, and data at present obtainable to, administration. Forward-looking statements typically embrace statements which are predictive in nature and rely upon or confer with future occasions or situations, and embrace phrases akin to “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and different related expressions amongst others. Forward-looking statements are primarily based on present beliefs and assumptions which are topic to dangers and uncertainties and aren’t ensures of future efficiency. Actual outcomes might differ materially from these contained in any forward-looking assertion on account of numerous elements, together with, with out limitation: the Company’s capacity to guard its mental property rights; the Company’s anticipated capital necessities, together with the Company’s anticipated money runway and the Company’s present expectations relating to its plans for future fairness financings; the Company’s dependence on extra financing to fund its operations and full the event and commercialization of its product candidates, and the dangers that elevating such extra capital might prohibit the Company’s operations or require the Company to relinquish rights to the Company’s applied sciences or product candidates; the Company’s restricted working historical past within the Company’s present line of business, which makes it tough to judge the Company’s prospects, the Company’s business plan or the probability of the Company’s profitable implementation of such business plan; the timing for the Company or its companions to provoke the deliberate scientific trials for PDS0101, PDS0203 and different Versamune^® and Infectimune™-based product candidates; the longer term success of such trials; the profitable implementation of the Company’s analysis and growth applications and collaborations, together with any collaboration research regarding PDS0101, PDS0203 and different Versamune^® and Infectimune™-based product candidates and the Company’s interpretation of the outcomes and findings of such applications and collaborations and whether or not such outcomes are enough to assist the longer term success of the Company’s product candidates; the success, timing and price of the Company’s ongoing scientific trials and anticipated scientific trials for the Company’s present product candidates, together with statements relating to the timing of initiation, tempo of enrollment and completion of the trials (together with the Company’s capacity to completely fund its disclosed scientific trials, which assumes no materials adjustments to our at present projected bills), futility analyses, shows at conferences and knowledge reported in an summary, and receipt of interim outcomes (together with, with out limitation, any preclinical outcomes or knowledge), which aren’t essentially indicative of the ultimate outcomes of the Company’s ongoing scientific trials; any Company statements about its understanding of product candidates mechanisms of motion and interpretation of preclinical and early scientific outcomes from its scientific growth applications and any collaboration research; and different elements, together with legislative, regulatory, political and financial developments not inside the Company’s management, together with unexpected circumstances or different disruptions to regular business operations arising from or associated to COVID-19. The foregoing evaluate of essential elements that would trigger precise occasions to vary from expectations shouldn’t be construed as exhaustive and must be learn along with statements which are included herein and elsewhere, together with the chance elements included within the Company’s annual and periodic reviews filed with the SEC. The forward-looking statements are made solely as of the date of this press launch and, besides as required by relevant regulation, the Company undertakes no obligation to revise or replace any forward-looking assertion, or to make some other forward-looking statements, whether or not on account of new data, future occasions or in any other case.

Versamune^® is a registered trademark and Infectimune™ is a trademark of PDS Biotechnology.

Investor Contacts:

Deanne Randolph
PDS Biotech
Phone: +1 (908) 517-3613
[email protected]

Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
[email protected]

Media
Dave Schemelia
Tiberend Strategic Advisors, Inc.
Phone: +1 (609) 468-9325
[email protected]